Investors have warmed to the biopharmaceutical sector since the beginning of the year, and they are anticipating that there will be an increase in the number of M&A transactions going forward. They are looking particularly at companies in the oncology space following Eli Lilly and Co.'s $8 billion buyout of Loxo Oncology Inc. last month.